Micrus Endovascular Receives FDA Approval For Intracranial Stent Clinical Trial

Micrus Endovascular Corporation (Nasdaq:MEND) announced that the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT) clinical trial application has been conditionally approved by the U.S. Food and Drug Administration (FDA).

More: continued here

Filed under: Cardiovascular on July 16th, 2008